|
Director, Biology
Dr. Davis is currently the Director of Biology at TransTech Pharma in North Carolina where he continues to pursue his passion for the discovery of innovative medicines for human disease. While at TTP he has implemented new discovery technologies for drug screening of therapeutic targets such as GPCRs, protein kinases, and tumor suppressor proteins, and initiated multiple oncology drug discovery programs. He also contributed to the discovery of several drug candidates for Type II diabetes and Cancer, which includes a novel orally administered agonist TTP054 of the GLP-1 receptor in phase I, and oral glucokinase activators currently in phase I/II, and the aurora kinase inhibitor TTP607.
His career began at Burroughs Wellcome Co. in 1990 where he studied novel inhibitors of pyrimidine metabolism and approaches for reversal of AZT-induced myelotoxicity. He contributed to the discovery of Eniluracil, a 5-FU modulator that blocks its catabolism and allows for oral administration.
At GlaxoSmithKline, he championed protein kinase inhibitor drug discovery while serving as a drug discovery project leader. He was a key member of the Cancer Research Committee that managed the portfolio of cancer programs, which included the dual EGFR/ErbB2 inhibitor project that produced Lapatinib. He served as the coordinator for the GSK research collaborative program with Duke and the University of North Carolina and managed all licensing opportunities within oncology.
Dr. Davis graduated from Virginia Polytechnic Institute and State University with a BS degree in Biochemistry and from the University of South Carolina with a PhD in Pharmacology. He has co-authored numerous scientific publications and patents, and contributed to several regulatory CTAs/IND and MAA documents and Investigator Brochures.
|